Neurol. praxi. 2016;17(2):100-103 | DOI: 10.36290/neu.2016.020

Role of T and B cells in pathogenesis of multiple sclerosis

MUDr. Zbyšek Pavelek1, prof. RNDr. Jan Krejsek, CSc.2, doc. MUDr. Martin Vališ, Ph.D.1
1 Neurologická klinika LF a FN Hradec Králové
2 Ústav klinické imunologie a alergologie, FN Hradec Králové

Multiple sclerosis is a chronic inflammatory demyelinating disease which affect central nervous system. This autoimmune disease manifests itself with various symptoms. This review explore the principle features of the immunopathology of multiple sclerosis. This include a role of T cells, B cells and cytokine netwoks promoting damage of the tissue. As the etiology of multiple sclerosis is unknown, available agents modify the disease course. Fundamental appreciation of the immmunopathology of multiple sclerosis leads to a broader understanding to mechanism of the agents, that are mentioned.

Keywords: multiple sclerosis, T cells, B cells

Published: February 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pavelek Z, Krejsek J, Vališ M. Role of T and B cells in pathogenesis of multiple sclerosis. Neurol. praxi. 2016;17(2):100-103. doi: 10.36290/neu.2016.020.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bacon KB, Harrison JK. Chemokines and their receptors in neurobiology: perspectives in physiology and homeostasis. J. Neuroimmunol., 2000; 104: 92-97. Go to original source... Go to PubMed...
    2. Constantinescu CS, Farooqi N, O'Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol. 2011; 164(4): 1079-1106. Go to original source... Go to PubMed...
    3. Costantino CM, Baecher-Allan C, Hafler DA. Multiple sclerosis and regulatory T cells. J Clin Immunol. 2008; 28(6): 697-706. Go to original source... Go to PubMed...
    4. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010; 33(2): 91-101. Go to original source... Go to PubMed...
    5. de Rosbo NK, Kaye JF, Eisenstein M, Mendel I, Hoeftberger R, Lassmann H, Milo R, Ben-Nun A. The myelin-associated oligodendrocytic basic protein region MOBP15-36 encompasses the immunodominant major encephalitogenic epitope(s) for SJL/J mice and predicted epitope(s) for multiple sclerosis-associated HLA-DRB1*1501. J Immunol. 2004; 173: 1426. Go to original source... Go to PubMed...
    6. Faure E. Multiple sclerosis and hepatitis B vaccination: could minute contamination of the vaccine by partial hepatitis B virus polymerase play a role through molecular mimicry? Med Hypotheses. 2005; 65(3): 509-520. Go to original source... Go to PubMed...
    7. Fox RJ, Kita M, Cohan SL, Henson LJ, Zambrano J, Scannevin RH, O'Gorman J, Novas M, Dawson KT, Phillips JT. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin. 2014; 30(2): 251-262. Go to original source... Go to PubMed...
    8. Freedman MS, Kaplan JM, Markovic-Plese S. Insights into the mechanisms of the therapeutic efficacy of alemtuzumab in multiple sclerosis. J Clin Cell Immunol. 2013; 4: 1-9. Go to original source...
    9. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med. 2006; 354: 942. Go to original source... Go to PubMed...
    10. Gandhi R, Laroni A, Weiner HL. Role of the innate immune system in the pathogenesis of multiple sclerosis. J. Neuroimmunol. 2009; 221: 7-14. Go to original source... Go to PubMed...
    11. Greenfield JG, Love S, Louis DN, Ellison D. Greenfield's neuropathology. 8. London: Hodder Arnold; 2008.
    12. Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand. 2011; 124(2): 75-84. Go to original source... Go to PubMed...
    13. Gudmundsdottir S, Svennerholm B, Kristensson K, Lycke E. Herpes simplex virus-enhanced production of autoantibodies against myelin basic protein in mice. Arch Virol. 1986; 88(1-2): 37-47. Go to original source... Go to PubMed...
    14. Hauser SL. The Charcot Lecture | beating MS: a story of B cells, with twists and turns. Mult Scler. 2015; 21(1): 8-21. Go to original source... Go to PubMed...
    15. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, Manolio TA. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 2009 Jun 9; 106(23): 9362-8367. Go to original source... Go to PubMed...
    16. Holick FM. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80: 1678S-1688S. Go to original source... Go to PubMed...
    17. International Multiple Sclerosis Genetics Consortium. A High-Density Screen for Linkage in Multiple Sclerosis. Am J Hum Genet. 2005; 77(3): 454-467. Go to original source... Go to PubMed...
    18. Kasper L, Shoemaker J. Multiple sclerosis immunology: The healthy immune system vs. the MS immune system. Neurology. 2010; 74: S2-S8. Go to original source... Go to PubMed...
    19. Komiyama KJ, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 2006; 177: 566-573. Go to original source... Go to PubMed...
    20. Krejsek J. Novinky v patogenezi roztroušené sklerózy. Co je skryto za disabilitou pacientů s RS. Remedia, 2014: S2-4.
    21. Liebert UG, Linington C, ter Meulen V. Induction of autoimmune reactions to myelin basic protein in measles virus encephalitis in Lewis rats. J Neuroimmunol. 1988; 17(2): 103-118. Go to original source... Go to PubMed...
    22. Lucchinetti CF, Bruck W, Lassmann H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol. 2004; 56: 308. Go to original source... Go to PubMed...
    23. Lünemann JD, Kamradt T, Martin R and Münz C. Epstein-Barr Virus: Environmental Trigger of Multiple Sclerosis? J. Virol. July 2007; 81(13): 6777-6784. Go to original source... Go to PubMed...
    24. Markowitz CE. Interferon-beta: mechanism of action and dosing issues. Neurology. 2007; 68(24, Suppl 4): S8-11. Go to original source... Go to PubMed...
    25. Matesanz F, González-Pérez A, Lucas M, Sanna S, Gayán J, Urcelay E, Zara I, Pitzalis M, Cavanillas ML, Arroyo R, Zoledziewska M, Marrosu M, Fernández O, Leyva L, Alcina A, Fedetz M, Moreno-Rey C, Velasco J, Real LM, Ruiz-Pe?a JL, Cucca F, Ruiz A, Izquierdo G. Genome-wide association study of multiple sclerosis confirms a novel locus at 5p13.1. PLoS One. 2012; 7(5): e36140. Go to original source... Go to PubMed...
    26. Pohl D, Krone K, Rostasy K, Kahler E, Brunner E, Lehnert M, Wagner HJ, Gärtner J, Hanefeld F High Seroprevalence of Epstein-Barr Virus in Children with Multiple Sclerosis. Neurology 2006; 67: 2063-2065. Go to original source... Go to PubMed...
    27. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302. Go to original source... Go to PubMed...
    28. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol. 2009; 27: 119-145. Go to original source... Go to PubMed...
    29. Rudick RA, Sandrock A. Natalizumab: ?4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurotherapeutics. 2004; 4: 571-580. Go to original source... Go to PubMed...
    30. Sallusto F, Impellizzieri D, Basso C, Laroni A, Uccelli A, Lanzavecchia A, Engelhardt B. T-cell trafficking in the central nervous system. Immunol Rev. 2012; 248(1): 216-227. Go to original source... Go to PubMed...
    31. Salzer J, Hallmans G, Nyström M, Stenlund H, Wadell G, Sundström P. Vitamin D as a protective factor in multiple sclerosis. Neurology. 2012; 79(21): 2140-2145. Go to original source... Go to PubMed...
    32. Soldan SS, Berti R, Salem N, Secchiero P, Flamand L, Calabresi PA, Brennan MB, Maloni HW, McFarland HF, Lin HC, Patnaik M, Jacobson S. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med. 1997; 3(12): 1394-1397. Go to original source... Go to PubMed...
    33. Steinman L. Multiple sclerosis: a two-stage disease. Nature Immunol., 2001; 2(9): 762-764. Go to original source... Go to PubMed...
    34. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998; 338: 278. Go to original source... Go to PubMed...
    35. Weller RO, Engelhardt B, Phillips MJ. Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways. Brain Pathol. 1996; 6(3): 275-288. Go to original source... Go to PubMed...
    36. Wucherpfennig KW and Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80: 695-705. Go to original source... Go to PubMed...
    37. Ziemssen T, Schrempf W. Glatiramer acetate: mechanisms of action in multiple sclerosis. Int Rev Neurobiol. 2007; 79: 537-570. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.